drugset / Trial / NCT05534165
Tecovirimat in Non-hospitalized Patients With Monkeypox
Phase 3
Suspended
120 enrolled
Marina Klein
CIHR Canadian HIV Trials Network · collabMcGill University Health Centre/Research Institute of the McGill University Health Centre · collabUnity Health Toronto · collabUniversity Health Network, Toronto · collabUniversity of British Columbia · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with presumptive or PCR confirmed monkeypox infection. The study will provide evidence on the efficacy and safety of Tecovirimat for laboratory-confirmed monkeypox in outpatients with monkeypox infection and determine the feasibility of conducting interventional monkeypox trials in Canada.
Timeline
- Start
- 2023-08-14
- Primary completion
- 2025-03-13
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tecovirimat | Small molecule | 600 mg | Oral |